Artiva Biotherapeutics (NASDAQ:ARTV) SVP Sells $27,885.95 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) SVP Heather Raymon sold 3,095 shares of Artiva Biotherapeutics stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $27,885.95. Following the sale, the senior vice president owned 148,228 shares of the company’s stock, valued at approximately $1,335,534.28. This represents a 2.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ ARTV opened at $8.55 on Wednesday. The company’s 50 day simple moving average is $8.32 and its 200 day simple moving average is $5.65. Artiva Biotherapeutics, Inc. has a fifty-two week low of $1.47 and a fifty-two week high of $14.53. The firm has a market capitalization of $211.36 million, a P/E ratio of -2.42 and a beta of 2.86.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Sell-side analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Institutional Trading of Artiva Biotherapeutics

A number of large investors have recently bought and sold shares of ARTV. Prelude Capital Management LLC acquired a new stake in Artiva Biotherapeutics during the 3rd quarter worth approximately $41,000. Bank of America Corp DE boosted its holdings in shares of Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after buying an additional 11,190 shares during the period. Bridgeway Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics during the second quarter worth $53,000. Qube Research & Technologies Ltd bought a new stake in shares of Artiva Biotherapeutics during the second quarter worth $58,000. Finally, Jane Street Group LLC acquired a new stake in shares of Artiva Biotherapeutics during the second quarter worth $67,000.

Wall Street Analysts Forecast Growth

ARTV has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. HC Wainwright raised their target price on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Wall Street Zen lowered Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Cantor Fitzgerald upped their price target on Artiva Biotherapeutics from $10.00 to $40.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Finally, Wedbush lifted their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Artiva Biotherapeutics presently has an average rating of “Moderate Buy” and an average price target of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.